Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 10 of 21 for:    tenosynovial giant cell tumor

Study of Vimseltinib for Tenosynovial Giant Cell Tumor (MOTION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05059262
Recruitment Status : Recruiting
First Posted : September 28, 2021
Last Update Posted : November 2, 2021
Information provided by (Responsible Party):
Deciphera Pharmaceuticals LLC

Brief Summary:

This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option.

The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.

Condition or disease Intervention/treatment Phase
Tenosynovial Giant Cell Tumor Pigmented Villonodular Synovitis Giant Cell Tumor of Tendon Sheath Tenosynovial Giant Cell Tumor, Diffuse Tenosynovial Giant Cell Tumor, Localized Drug: vimseltinib Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)
Actual Study Start Date : October 14, 2021
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : July 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Part 1/Part 2 - vimseltinib/vimseltinib
Participants receive blinded treatment of 30 mg twice a week (biw) vimseltinib for 24 weeks in Part 1 and continue on 30 mg biw vimseltinib in Part 2
Drug: vimseltinib
CSF1R inhibitor
Other Name: DCC-3014

Placebo Comparator: Part 1/Part 2 - placebo/vimseltinib
Participants receive blinded treatment of 30 mg twice a week (biw) matching placebo for 24 weeks in Part 1 and have option to receive 30 mg biw vimseltinib in Part 2
Drug: vimseltinib
CSF1R inhibitor
Other Name: DCC-3014

Drug: Placebo

Primary Outcome Measures :
  1. Objective Response Rate (ORR= complete response [CR]+partial response [PR]) per RECIST Version 1,1 [ Time Frame: Baseline to Week 25 (Cycle 7, Day 1) ]
    Assessed by central read using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1

Secondary Outcome Measures :
  1. ORR per Tumor Volume Score (TVS) [ Time Frame: Baseline to Week 25 (Cycle 7, Day 1) ]
    Assessed by central read using Tumor Volume Score (TVS). TVS is a semi-quantitative MRI scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor.

  2. Range of motion (ROM) [ Time Frame: Baseline to Week 25 (Cycle 7, Day 1) ]
    Mean change from baseline in active ROM of the affected joint, relative to a reference standard at Week 25

  3. Physical function [ Time Frame: Baseline to Week 25 (Cycle 7, Day 1) ]
    Mean change from baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) physical function score at Week 25

  4. Worst stiffness [ Time Frame: Baseline to Week 25 (Cycle 7, Day 1) ]
    Mean change from baseline in the Worst Stiffness Numeric Rating Scale (NRS) score at Week 25

  5. Quality of life (QoL) [ Time Frame: Baseline to Week 25 (Cycle 7, Day 1) ]
    Mean change from baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 25

  6. Worst pain [ Time Frame: Baseline to Week 25 (Cycle 7, Day 1) ]
    Proportion of responders, with a response defined as at least a 30% improvement in the mean Brief Pain Inventory (BPI) Worst Pain NRS score without a 30% or greater increase in narcotic analgesic use at Week 25

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients ≥18 years of age
  2. TGCT for which surgical resection is not an option (tumor biopsy to confirm diagnosis required if no histology/pathology available at screening)
  3. Symptomatic disease as defined as at least moderate pain per BPI Worst Pain or at least moderate stiffness per Worst Stiffness NRS item (defined as a score of 4 or more, with 10 describing the worst condition) within the screening period, prior to the first dose, and documented in the medical record
  4. Participants should complete 14 consecutive days of questionnaires during the screening period and must meet minimum requirements as outlined in study protocol
  5. Must have stable analgesic regimen, as judged by the investigator, for at least 2 weeks prior to first dose of study drug
  6. Must have at least 1 measurable lesion according to RECIST Version 1.1, with a minimum tumor size of 2cm
  7. Adequate organ and bone marrow function
  8. If a female of childbearing potential, must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements
  9. Must provide signed consent to participate in the study and is willing to comply with study-specific procedures
  10. Willing and able to complete the patient-reported outcome (PRO) assessments on an electronic device

Exclusion Criteria:

  1. Previous use of systemic therapy targeting colony stimulating factor 1 (CSF1) or CSFR1 receptor (CSF1R); previous therapy with imatinib and nilotinib is allowed
  2. Received therapy for TGCT, including investigational therapy within 14 days prior to the administration of study drug or within 28 days for therapies with a half-life longer than 3 days or an unknown half-life prior to the administration of study drug
  3. Known metastatic TGCT or other active cancer that requires concurrent treatment (exceptions will be considered on a case-by-case basis)
  4. QT interval corrected by Fridericia's formula (QTcF) >450 ms in males or >470 ms in females or history of long QT syndrome
  5. Concurrent treatment with any study-prohibited medications
  6. Major surgery within 14 days of the first dose of study drug
  7. Any clinically significant comorbidities
  8. Active liver or biliary disease including evidence of fatty liver, nonalcoholic steatohepatitis (NASH), or cirrhosis
  9. Malabsorption syndrome or other illness that could affect oral absorption
  10. Known active human immunodeficiency virus (HIV), active or chronic hepatitis B, active or chronic hepatitis C, or known active mycobacterium tuberculosis infection
  11. If female, the participant is pregnant or lactating
  12. Known allergy or hypersensitivity to any component of the study drug
  13. Contraindication to MRI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05059262

Layout table for location contacts
Contact: Clinical Team 785-830-2100

Layout table for location information
United States, California
City of Hope Not yet recruiting
Duarte, California, United States, 91010
Contact: Mark Agulnik         
United States, Colorado
University of Colorado Not yet recruiting
Aurora, Colorado, United States, 80045
Contact: Breelyn Wilky         
United States, Massachusetts
Dana Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Andrew Wagner         
United States, Minnesota
Mayo Clinic Rochester Not yet recruiting
Rochester, Minnesota, United States, 55905
Contact: Scott Okuno         
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Vinod Ravi         
Chris O'Brien Lifehouse Not yet recruiting
Camperdown, Australia
Contact: Vivek Bhadri         
McGill University Recruiting
Montréal, Canada
Contact: Thierry Alcindor         
Princess Margaret Hospital Not yet recruiting
Toronto, Canada
Contact: Albiruni Razak         
Korea, Republic of
Seoul National University Hospital Not yet recruiting
Seoul, Korea, Republic of
Contact: Ilkyu Han         
Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy Not yet recruiting
Warsaw, Poland
Contact: Piotr Rutkowski         
Hospital de la Santa Creu i Sant Pau Not yet recruiting
Barcelona, Spain
Contact: Antonio Lopez Pousa         
Hospital Universitario Vall d'Hebron Not yet recruiting
Barcelona, Spain
Contact: Cesar Serrano         
Universitäts-Kinderspital beider Basel (UKBB) Not yet recruiting
Basel, Switzerland
Contact: Andreas Krieg         
United Kingdom
Cancer & Haematology Centre, The Churchill Hospital - Oxford University Hospitals NHS Foundation Trust Not yet recruiting
London, United Kingdom
Contact: Sarah Pratap         
Sponsors and Collaborators
Deciphera Pharmaceuticals LLC
Layout table for additonal information
Responsible Party: Deciphera Pharmaceuticals LLC Identifier: NCT05059262    
Other Study ID Numbers: DCC-3014-03-001
First Posted: September 28, 2021    Key Record Dates
Last Update Posted: November 2, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Giant Cell Tumors
Giant Cell Tumor of Tendon Sheath
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Synovitis, Pigmented Villonodular
Joint Diseases
Musculoskeletal Diseases
Muscular Diseases